Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

ClinicalTrials.gov ID: NCT03344458

Public ClinicalTrials.gov record NCT03344458. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

enliGHten: A Multicenter, Phase 3, Long-Term, Open-Label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children With Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial

Study identification

NCT ID
NCT03344458
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Ascendis Pharma A/S
Industry
Enrollment
298 participants

Conditions and interventions

Eligibility (public fields only)

Age range
1 Year to 18 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 18, 2017
Primary completion
Feb 20, 2023
Completion
Feb 20, 2023
Last update posted
Jul 6, 2026

2017 – 2023

United States locations

U.S. sites
22
U.S. states
14
U.S. cities
21
Facility City State ZIP Site status
Ascendis Pharma Investigational Site Birmingham Alabama 35233
Ascendis Pharma Investigational Site Los Angeles California 90048
Ascendis Pharma Investigational Site Orange California 92868
Ascendis Pharma Investigational Site Sacramento California 95821
Ascendis Pharma Investigational Site Centennial Colorado 80112
Ascendis Pharma Investigational Site Jacksonville Florida 32207
Ascendis Pharma Investigational Site Orlando Florida 32806
Ascendis Pharma Investigational Site Tallahassee Florida 32308
Ascendis Pharma Investigational Site Saint Paul Minnesota 55102
Ascendis Pharma Investigational Site Jackson Mississippi 39216
Ascendis Pharma Investigational Site Lebanon New Hampshire 03756
Ascendis Pharma Investigational Site Mineola New York 11501
Ascendis Pharma Investigational Site New York New York 10029
Ascendis Pharma Investigational Site Cleveland Ohio 44195
Ascendis Pharma Investigational Site Oklahoma City Oklahoma 73104
Ascendis Pharma Investigational Site Portland Oregon 97227
Ascendis Pharma Investigational Site Portland Oregon 97239
Ascendis Pharma Investigational Site Dallas Texas 75390
Ascendis Pharma Investigational Site Fort Worth Texas 76104
Ascendis Pharma Investigational Site Charlottesville Virginia 22908
Ascendis Pharma Investigational Site Norfolk Virginia 23507
Ascendis Pharma Investigational Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03344458, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 6, 2026 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03344458 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →